Products with Anxiolytic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1011 | Asiaticoside |
| Asiaticoside, a biochemical modulator, which has antioxidant, anti-inflammatory, antipyretic, anxiolytic-like, anti-gastric ulcers, hepatoprotective, and antidepressant-like effects, it also exhibits significant wound healing activity in normal as well as delayed healing models. Asiaticoside suppressed collagen expression and TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts. It and its derivatives can be regarded as reasonable candidates for a therapeutic Alzheimer's disease drug that protects neurons from Abeta toxicity. | |
| BCN1178 | Salvigenin |
| Salvigenin, a potent hMAO-A [monoamine oxidases (MAOs)]inhibitor, has neuroprotective, antitumor and immunomodulatory effects, it has potential to ameliorate Streptozotocin-induced diabetes mellitus and heart complications in rats. Salvigenin has dose-dependent analgesic effect so that it can be useful in controlling of inflammations, acute and chronic pain. | |
| BCN1232 | DL-5-Hydroxytryptophan |
| 5-Hydroxytryptophan (5-HTP) is the precursor of serotonin , has been widely used as a dietary supplement to raise serotonin level, it is an effective drug against depression, insomnia, obesity, chronic headaches, etc. 5-HTP supplementation can inhibit endothelial serotonylation, leukocyte recruitment, and allergic inflammation, it also can reduce the symptoms of anxiety/depression of that patients with allergy/asthma. 5-HTP may be involved in inducing the female to stay in copula and delay egg-laying to prevent re-mating of the female. | |
| BCN1680 | Ginkgolide A |
| Ginkgolide A is a platelet-activating factor antagonist, it can inhibit the neurotoxicity of prions or amyloid-beta1-42, may be relevant treatments for prion or Alzheimer's diseases.Ginkgolide A has neuroprotective, and anxiolytic-like effects, it is widely used for the treatment of cardiovascular diseases and diabetic vascular complications, which might be achieved through regulating the STAT3-mediated pathway. | |
| BCN2187 | 4-Aminobutanoic acid |
| Lower CSF 4-Aminobutanoic acid may explain increasing severity of psychic anxiety in major depression with increasing age, suggests treatments targeting the 4-Aminobutanoic acid ergic system should be evaluated in treatment-resistant anxious major depression and in older patients. | |
